Analysts Are Bullish on Top Healthcare Stocks: Kiniksa Pharmaceuticals Ltd (KNSA), Stemline Therapeutics Inc (STML)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kiniksa Pharmaceuticals Ltd (KNSAResearch Report) and Stemline Therapeutics Inc (STMLResearch Report) with bullish sentiments.

Kiniksa Pharmaceuticals Ltd (KNSA)

In a report released yesterday, David Nierengarten from Wedbush reiterated a Buy rating on Kiniksa Pharmaceuticals Ltd, with a price target of $30. The company’s shares closed last Monday at $11.10, close to its 52-week low of $10.70.

According to, Nierengarten is a 5-star analyst with an average return of 24.8% and a 51.6% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Stemline Therapeutics Inc, and Voyager Therapeutics Inc.

The the analyst consensus on Kiniksa Pharmaceuticals Ltd is currently a Hold rating.

See today’s analyst top recommended stocks >>

Stemline Therapeutics Inc (STML)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics Inc today and set a price target of $35. The company’s shares closed last Monday at $15.47.

Selvaraju observed:

“Our estimated market value of the firm is $1.75B, which includes the asset value for tagraxofusp and 15% discount rate and 2% terminal growth rate. The probability of success is 66% for tagraxofusp in indications beyond BPDCN and 45% for SL-701. Assuming roughly 50.1M shares outstanding at the end of 2Q20, this leads to a 12-month price target of approximately $35 per share.”

According to, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.7% and a 27.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.

Stemline Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $27.25, implying a 75.8% upside from current levels. In a report issued on August 2, Wedbush also upgraded the stock to Buy with a $20 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.